Isaac Johnson is currently the CEO at Verinnogen, where Isaac leads the development of innovative tools for pre-clinical cancer research. Prior to their role as CEO, Isaac worked as a Scientist at Artios Pharma Ltd and held various research positions at the University of Cambridge. Isaac earned a PhD in Oncology and Cancer Biology from the University of Cambridge after completing a BSc in Biomedicine from the University of East Anglia.
This person is not in any teams